+1 915 229 3004 (U.S.) | 
+44 7452 242832 (U.K.)
+1 915 229 3004 (U.S.) | +44 7452 242832 (U.K.)
Global Hydroxychloroquine Market Size was valued at USD 0.2 Billion in 2022. The Hydroxychloroquine market Application is projected to grow from USD 0.33 Billion in 2023 to USD 0.7 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 26.80% during the forecast period (2023 - 2032). AbbVie Inc. received FDA approval for HUMIRA (adalimumab), a medication that can be used to treat mild to severe hidradenitis suppurativa.High rates of malaria and rheumatoid arthritis, a surge in the number of new goods being produced and licensed, disease outbreaks such the coronavirus disease (COVID-19), are the key market drivers enhancing the market growth.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
As of April 2020, the novel coronavirus is thought to have caused 2 million COVID-19 active cases, along with an estimated 126,758 linked deaths. In March 2020, the WHO declared COVID-19 to be a pandemic. Because there is no available specialized medicinal medication for COVID-19 and it will take more than 18 months for the vaccine to be available on the market, healthcare regulators have been forced to approve additional drugs for illness control and management. One such promise was shown by hydroxychloroquine. Patients with COVID-19 were given the drug in multiple studies in China, France, and the US. The results of the individuals who took this drug looked promising. This led to the U.S. FDA issuing an Emergency Use Authorization (EUA) for the oral formulation of the drug for COVID-19 patients. It is projected that this growth in demand will help hydroxychloroquine's market.
Over the past few years, malaria prevalence has increased in the developing countries of Asia and the Pacific. The majority of malaria cases in the region, based on estimates, occur in India. Hydroxychloroquine is one of the most often used drugs to treat malaria in the country. The World Malaria Report 2019 states that 6 million persons in India alone have malaria diagnoses. According to estimates from the World Health Organization (WHO), 228 million people globally acquired malaria in 2018. In addition, mosquitoes that are pesticide-resistant have hastened the spread of malaria in developing and underdeveloped countries. Despite an increase in malaria cases and vector pesticide resistance during the projected period, this business is anticipated to grow favorably.
The market is expected to rise significantly as a result of rising demand for new hydroxychloroquine and greater generic drug penetration. Additionally, greater government funding is predicted to have a substantial impact on the business, leading to higher product approval. It is anticipated that the use of hydroxychloroquine drugs will increase because to the increased patient awareness of COVID-19 and the global influx of new generic meds. Only the US had 609,516 patients with COVID-19 as of April 15, 2020, according to Johns Hopkins University. increased clinical trials to evaluate hydroxychloroquine's effectiveness in treating COVID-19 and increased public awareness of disease remittance therapies are expected to support revenue growth. Thus, driving the Hydroxychloroquine market revenue.
The global Hydroxychloroquine market segmentation, based on Application, includes rheumatoid arthritis, coronavirus (COVID-19), malaria, lupus erythematosus, Q-fever, and porphyria cutnea tarda (PCT). Rheumatoid arthritis segment dominated the global market in 2022. This may be related to a rise in rheumatoid arthritis cases, which present with a range of symptoms like stiffness, swelling, and joint soreness along with persistent pain and the inability to do daily activities. Over time, this disorder can limit a patient's mobility and cause irreparable joint damage. If this illness is not treated, it may limit movement and raise the possibility that a joint replacement will be necessary.
The World Health Organisation estimates that more than 23 million individuals worldwide suffer from rheumatoid arthritis. As a result, patients are getting better benefits from combination medicines in the rheumatoid arthritis market. Generic medications for the target disease are becoming more readily available, showing promising outcomes, and being less expensive, which are supporting the segment's growth.
The global Hydroxychloroquine market segmentation, based on Strength, includes 500 mg and 200 mg. 500 mg segment dominated the global Hydroxychloroquine market in 2022. The 500 mg COVID-19 disease medication is used to treat the condition's severe versions. It is hoped that this drug will gain more traction. The 200 mg drugs are also used to treat rheumatoid arthritis, lupus erythematosus, malaria, and coronavirus.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
Hydroxychloroquine Regional Insights
Insights into the markets in North America, Europe, Asia-Pacific, and the rest of the world are provided by the study.The Asia Pacific Hydroxychloroquine market dominated this market in 2022 (45.80%). The prevalence of disease sufferers is increasing in several emerging countries as a result of low disease awareness. This is anticipated to help the market in APAC along with rising healthcare spending, the presence of important manufacturers like Zydus, Cadila, Novartis, and Sun Pharmaceuticals, and an increase in product approvals. Due to the increasing demand for target medications for disease reversal, regional markets are anticipated to expand throughout the projected period. Moreover, In the Asia-Pacific region, the Indian Hydroxychloroquine Market market had the quickest rate of growth while China's Hydroxychloroquine Market market had the greatest market share.
Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Download Free Sample to learn more about this report
Source: Secondary Research, Primary Research, RESEARCH LAYER Database and Analyst Review
The North America Hydroxychloroquine Market is expected to register significant growth from 2023 to 2032. Increased patient awareness of disease-remitting treatments, an increase in the prevalence of RA and COVID-19, and high public and private healthcare spending are all contributing to the region's growth. Furthermore, the World Health Organization estimates that by the end of 2040, 54.4 million persons in the country may have rheumatoid arthritis. Furthermore, it is expected that easy access to high-quality healthcare, generous reimbursement systems, a strong trial pipeline, and the approval of cutting-edge medications will drive revenue growth in North America. Further, In the North American area, the U.S. Hydroxychloroquine Market market had the biggest market share, while the Canada Hydroxychloroquine Market market had the quickest rate of expansion.
Europe Hydroxychloroquine market accounted for the healthy market share in 2022. Because of governmental constraints, the availability of substantial research facilities, and increased awareness of medication safety, the market in Europe is predicted to expand. Further, In the European region, the German Hydroxychloroquine Market market had the biggest market share, and the U.K. Hydroxychloroquine Market market had the quickest rate of growth.
Leading industry companies are making significant R&D investments in order to diversify their product offerings, which will drive the Hydroxychloroquine Market market's expansion. Important market developments include new product releases, contractual agreements, mergers and acquisitions, greater investments, and collaboration with other organizations. Market participants are also engaging in a number of strategic actions to increase their global footprint. The Hydroxychloroquine Market sector needs to provide affordable products if it wants to grow and thrive in a more competitive and challenging market environment.
One of the primary business strategies employed by manufacturers in the worldwide Hydroxychloroquine Market industry to assist customers and expand the market sector is local manufacturing to reduce operational costs. Some of the biggest benefits to medicine have recently come from the Hydroxychloroquine Market sector. Major players in the Hydroxychloroquine market, including Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Mylan N.V., Novartis International AG, Hikma Pharmaceuticals, Ipca Laboratories, Apotex Corporation, Cipla, Wallace Pharmaceuticals, Covis Pharmaceuticals Ltd., Lupin Pharmaceutical, McW Healthcare, Intas Pharmaceuticals, Macleods Pharmaceuticals, Hanlim Pharmaceutical, Concordia Healthcare, Taj Pharmaceuticals, Laurus Labs Limited, Shanghai Pharmaceuticals Holding, and Kyung Poong, are attempting to increase market demand by investing in research and development operations.
Zydus Lifesciences Ltd. (Zydus Lifesciences), originally Cadila Healthcare Ltd., is an integrated global healthcare supplier. It locates, develops, produces, and sells a variety of medical products. The company's product line includes formulations, wellness, and animal health items as well as active pharmaceutical ingredients (APIs). The therapeutic areas covered by Zydus Lifesciences' products include women's health, neurology, pain management, cancer, cardiovascular disease, and inflammation. It conducts research to develop new chemical entities, biologics, vaccines, and biosimilars. Brazil, the US, Goa, Maharashtra, Sikkim, and Himachal Pradesh in India are among the countries where the company has production facilities. It is present in the US, Europe, South Africa, Japan, and Brazil in addition to other growing markets. Ahmedabad, Gujarat, India, is home to Zydus Lifesciences' corporate headquarters. Zydus Cadila and Ipca Labs have backward integrated HCQ production capability with the objective of boosting manufacturing capacity by 5–6 times to 70 MT per month by April 2020. The millions of people who suffer from the target diseases will have more therapy alternatives now.
The creation, manufacture, and marketing of prescription and over-the-counter medications, as well as items for eye care, are the specialties of a healthcare company by the name of Novartis AG (Novartis). It provides medications for treating solid tumors, immune system problems, infections, cardiovascular disease, dermatological problems, neurological problems, ophthalmic and respiratory illnesses, cancer, and neurological abnormalities, among other conditions. The company sells biosimilars and generic drugs through Sandoz. Novartis conducts research in several disease-related sectors through the Novartis Institutes for BioMedical Research (NIBR). The company operates a network of companies and offices in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. The Novartis corporate headquarters are located in Basel, Switzerland. In March 2020, Novartis International AG started sending 30 million doses of hydroxychloroquine tablets to the US Department of Health and Human Services (HHS) for controlled clinical studies to evaluate the effectiveness of hydroxychloroquine in people who have tested positive for coronavirus disease (COVID 19).
· Sanofi S.A.
· Teva Pharmaceutical Industries Ltd.
· Zydus Cadila
· Mylan N.V.
· Novartis International AG
· Hikma Pharmaceuticals
· Ipca Laboratories
· Apotex Corporation
· Cipla
· Wallace Pharmaceuticals
· Covis Pharmaceuticals Ltd.
· Lupin Pharmaceutical
· McW Healthcare
· Intas Pharmaceuticals
· Macleods Pharmaceuticals
· Hanlim Pharmaceutical
· Concordia Healthcare
· Taj Pharmaceuticals
· Laurus Labs Limited
· Shanghai Pharmaceuticals Holding
· Kyung Poong
June 2021: According to the company's release, Catalent, Inc. will acquire RheinCell Therapeutics GmbH, a well-known developer and manufacturer of GMP-grade human induced pluripotent stem cells. This acquisition will enhance the company's current stem cell therapy method development and production capabilities.
December 2020: Lonza said that they have strengthened their partnership with Aurinia Pharmaceuticals in order to increase the manufacturing capacity for effective voclosporin manufacture and manufacturing.
· Rheumatoid Arthritis
· Coronavirus (COVID-19)
· Malaria
· Lupus Erythematosus
· Q-fever
· Porphyria Cutnea Tarda (PCT)
· 500 mg
· 200 mg
· North America
- US
- Canada
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Australia
- Rest of Asia-Pacific
· Rest of the World
- Middle East
- Africa
- Latin America
|
Report Attribute/Metric |
Details |
|
Market Size 2022 |
USD 0.2 Billion |
|
Market Size 2023 |
USD 0.33 Billion |
|
Market Size 2032 |
USD 0.7 Billion |
|
Compound Annual Growth Rate (CAGR) |
26.80% (2023-2032) |
|
Base Year |
2022 |
|
Market Forecast Period |
2023-2032 |
|
Historical Data |
2018- 2022 |
|
Market Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
Application, Strength, and Region |
|
Geographies Covered |
North America, Europe, Asia Pacific, and the Rest of the World |
|
Countries Covered |
The U.S., Canada, German, France, U.K, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil |
|
Key Companies Profiled |
Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Mylan N.V., Novartis International AG, Hikma Pharmaceuticals, Ipca Laboratories, Apotex Corporation, Cipla, Wallace Pharmaceuticals, Covis Pharmaceuticals Ltd., Lupin Pharmaceutical, McW Healthcare, Intas Pharmaceuticals, Macleods Pharmaceuticals, Hanlim Pharmaceutical, Concordia Healthcare, Taj Pharmaceuticals, Laurus Labs Limited, Shanghai Pharmaceuticals Holding, and Kyung Poong |
|
Key Market Opportunities |
Increased emphasis by manufacturers to utilize the growth |
|
Key Market Dynamics |
Disease outbreaks such as coronavirus disease (COVID-19), high prevalence of malaria and rheumatoid arthritis, and increasing product launches and approvals |
The global Hydroxychloroquine Market was valued at USD 0.2 billion in 2022, and it is estimated to reach USD 0.7 billion by 2032.
The global market is projected to grow at a CAGR of 26.80% during the forecast period, 2023-2032.
Asia Pacific had the largest share in the global market
The key players in the market are Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zydus Cadila, Mylan N.V., Novartis International AG, Hikma Pharmaceuticals, Ipca Laboratories, Apotex Corporation, Cipla, Wallace Pharmaceuticals, Covis Pharmaceuticals Ltd., Lupin Pharmaceutical, McW Healthcare, Intas Pharmaceuticals, Macleods Pharmaceuticals, Hanlim Pharmaceutical, Concordia Healthcare, Taj Pharmaceuticals, Laurus Labs Limited, Shanghai Pharmaceuticals Holding, and Kyung Poong
The Coronavirus (COVID-19) Chromatography Application dominated the market in 2022.
The 500 mg Strength had the largest share in the global market.
Research on the market is done by industry professionals who provide personalized insights on the industry structure, market segmentation, Type assessment, competitive landscape (CL), along with penetration, and emerging trends. In addition to years of professional experience in their various fields and sectors, their analysis is largely based on primary interview (60%) and secondary research (40%) as well as years of professional experience. In addition, our researchers forecast the market's direction over the following seven years by examining past trends and the market's current position. Additionally, various trends of segments and categories that are geographically portrayed are studied and estimated using primary and secondary research.
The key level executives (VP, CEO, Marketing Directors, and Business Development Managers) of the major industry participants who are active and prominent as well as mid-scale businesses operating in this market were interviewed in-depth for this supply-side report by overall Global Market Research.
Extensive primary research was conducted to gain a deeper grasp of the market and industry. Both primary and secondary research, as well as years of pertinent professional experience, are used to support the analysis. By analyzing past and present market patterns, our experts were able to forecast the market's course over the following seven years. For the geographically offered categories in the list of market tables, it differs per category. In connection with the Global Market research report, we also conducted a number of primary interviews with senior level executives (VP, CEO's, Directors, Marketing Directors, Business Development Managers, CFOs, Technical Consultants, Key Opinion Leaders, Industry Experts, Decision Matrix Authorities, and other crucial individuals) of the key industry players who dominated the Global market.
The primary purpose of secondary research was to gather, identify, and validate the information necessary for the thorough, technical, market-focused, and commercial analysis of the global market. With the use of this study, it was also possible to classify and segment the market in accordance with market trends, geographic markets, and regional considerations linked to market type. Analysts have gathered data in the Distribution Channel for the study of the market from reliable sources including annual reports, journals, white papers, corporate presentations, company websites, international organizations of Energy and Power manufacturers, credible paid databases, and many others to gather reliable intel.
Both top-down and bottom-up methodologies were employed to assess the accuracy of the global market size. The market for as a whole was estimated using these methods for a number of different dependent submarkets. Secondary research was used to address the major industry players, and primary and secondary research was used to calculate their market shares in the various regions. This complete intellectual process includes reading the annual and financial reports of the top market participants and conducting in-depth interviews with top industry executives (VP, CEO, Marketing Directors, and Business Development Managers) to gain important industry insights.
Through reliable secondary sources and validated primary sources, the classification of the global markets and their geographic percentage splits were established. To obtain the final qualitative and quantitative data, all relevant variables that might have an impact on the market under investigation have been taken into consideration, inspected in great depth, verified through primary research, and assessed. This information was collected, added to, and thoroughly examined by professional analysts before being provided in this report. The process used to estimate the overall market size for this study is depicted in the following image as an example.
Report Code :
RL65266
Published on :
Sep 2023
Request a Free Sample Report
Speak to Analyst